Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea

Table 3 Multivariate Cox-regression model

	Progression-free survival (PFS)		Overall survival (OS)
	HR (95% CI)	p Value	HR (95% CI)	p Value
Age ≤ 35	1.16 (0.81–1.66)	0.431	1.21 (0.76–1.93)	0.425
ECOG ≥1	1.55 (1.10–2.16)	0.011	1.51 (0.96–2.36)	0.074
Visceral metastasis	1.27 (0.91–1.78)	0.156	1.25 (0.79–2.00)	0.344
PgR-negative	1.61 (0.99–2.62)	0.056	1.56 (0.85–2.85)	0.152
Initial endocrine therapy	0.59 (0.41–0.88)	0.009	0.73 (0.43–1.22)	0.224
Chemotherapy-endocrine therapy	0.34 (0.21–0.55)	< 0.001	0.40 (0.20–0.78)	0.007

HR hazard ratio, 95% CI 95% confidence interval, ECOG Eastern Cooperative Oncology Group, PgR progesterone receptor. All treatments were begun prior to disease progression

ISSN: 1471-2407